港股開盤 | 恆指低開0.73%,心通醫療-B上市首日高開76.23%
【三大指數】
恆生指數開盤下跌213.92點,跌幅0.73%,報29093.54點;
國企指數開盤下跌82.48點,跌幅0.71%,報11569.36點;
紅籌指數開盤下跌18.61點,跌幅0.46%,報4013.69點。
【新股首日】
上市首日,心通醫療-B高開76.23%。
【異動個股】
中國生物製藥高開6.96%,建議人民幣股份發行並在上交所科創板上市。
華晨中國低開3.6%,注意到有媒體報道中國一汽可能收購公司股份並私有化,公司澄清並不知曉媒體報道內容的來源。
東陽光藥高開0.92%,四種藥品中標全國集中採購。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.